Brief: Ionis Announces License Agreement With Recordati For Zilganersen In Alexander Disease (Axd) In All Countries Outside The U.S.
25/06/2026 08:01
BRIEF-Ionis Announces License Agreement With Recordati For Zilganersen In Alexander Disease (Axd) In All Countries Outside The U.S. June 25 (Reuters) - Ionis Pharmaceuticals Inc IONS.O:
IONIS ANNOUNCES LICENSE AGREEMENT WITH RECORDATI FOR ZILGANERSEN IN ALEXANDER DISEASE (AXD) IN ALL COUNTRIES OUTSIDE THE U.S.
IONIS PHARMACEUTICALS - TO RETAIN U.S. COMMERCIAL RIGHTS AND LEAD GLOBAL DEVELOPMENT OF ZILGANERSEN
IONIS PHARMACEUTICALS - PLANS INDEPENDENT U.S. LAUNCH OF ZILGANERSEN; FDA PDUFA DATE SET FOR SEPTEMBER 22
Source text: ID:nBwb537Nya
Further company coverage: IONS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ionis Pharmaceuticals
See all newsUS FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment (updated)
US FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment
Focus: AI companies run virtual drug trials, aim to improve success of human studies
Brief: Ionis Pharmaceuticals Says Ulefnersen Demonstrates Favorable Safety And Tolerability Profile
Otsuka, Ionis' experimental ALS drug meets main goal in late-stage study